文献速递新药、器械与细胞基因治疗研发基础与转化研究

RPGR突变X连锁视网膜色素变性的首个人体基因治疗试验初步结果

Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR.
PubMed 文献 · Nat Med · 2020-02-24

这是一项针对RPGR突变所致X连锁视网膜色素变性的首个人体1/2期剂量递增临床试验,共18例患者,随访至6个月。主要终点为安全性,高剂量组出现可经类固醇控制的视网膜下炎症,其余无显著安全担忧,达到预设主要终点;6例患者视野从1个月起改善并维持至末次随访。

要点

  • AAV8-coRPGR视网膜下注射总体安全,高剂量组可出现类固醇responsive视网膜下炎症。
  • 6例患者视野从1个月起改善并维持至末次随访。
  • 次要终点包括视力、微视野和中心视网膜厚度。

核心结论

  • 视网膜下注射AAV8-coRPGR达到预设主要安全性终点,高剂量组仅见类固醇responsive视网膜下炎症。
  • 6例患者视野从1个月起改善并维持至末次随访。

研究设计与样本

  • 首个人体1/2期剂量递增临床试验,纳入18例RPGR突变所致X连锁视网膜色素变性患者,随访至6个月。

主要发现

  • 高剂量组出现类固醇responsive视网膜下炎症,无其他显著安全担忧。
  • 6例患者视野从1个月起改善并维持至末次随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Retinal gene therapy has shown great promise in treating retinitis pigmentosa (RP), a primary photoreceptor degeneration that leads to severe sight loss in young people. In the present study, we report the first-in-human phase 1/2, dose-escalation clinical trial for X-linked RP caused by mutations in the RP GTPase regulator (RPGR) gene in 18 patients over up to 6 months of follow-up (https://clinicaltrials.gov/: NCT03116113). The primary outcome of the study was safety, and secondary outcomes included visual acuity, microperimetry and central retinal thickness. Apart from steroid-responsive subretinal inflammation in patients at the higher doses, there were no notable safety concerns after subretinal delivery of an adeno-associated viral vector encoding codon-optimized human RPGR (AAV8-coRPGR), meeting the pre-specified primary endpoint. Visual field improvements beginning at 1 month and maintained to the last point of follow-up were observed in six patients.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020. PMID: 32094925. doi:10.1038/s41591-020-0763-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。